News

Laurent Pharmaceuticals announces positive Phase 1b topline results for LAU-7b in Cystic Fibrosis

15 June 2015

LAU-7b is safe and well tolerated by adult Cystic Fibrosis (CF) patientsThe pharmacokinetic profile fully achieved the protocol dose selection rationaleStudy...

Read More

A new orphan disease-focused company

5 December 2014

MSBi Valorisation announces the creation of Laurent Pharmaceuticals, a new biopharmaceutical company specializing in rare diseases.MSBi Valorisation announces the creation of...

Read More

EVENTS

Laurent Pharmaceuticals presents data with LAU-7b in Idiopathic Pulmonary Fibrosis at the 2024 ATS International Conference, May 17-22, San Diego, CA, USA
Laurent Pharma to participate to BIO International Convention,  June 3-6 2024, San Diego, CA, USA

Laurent Pharma to participate to BIO International Convention, June 5-8, 2023, Boston, MA

Laurent Pharma to participate to BIO International Convention, June 13-16, 2022 – San Diego, CA
Laurent Pharma to participate to BIO-Europe Spring, March 28-31, 2022